Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27929918 | 1.00 | AKR1B1 (0.37) | AKR1B1 | |
| SCHEMBL14603586 | 0.77 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL4043864 | 0.69 | — | — | |
| SCHEMBL15418572 | 0.66 | — | — | |
| SCHEMBL3482824 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL11035270 | 0.64 | — | — | |
| SCHEMBL21345129 | 0.62 | GRM2 (0.31) | — | |
| SCHEMBL6843815 | 0.62 | — | — | |
| SCHEMBL28159972 | 0.62 | — | — | |
| SCHEMBL1764290 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111481562-A | Application of apramycin in preparation of bacterial infectious disease treatment | 苏黎世大学 | 2020-08-04 | — | — | CN | disclosed |
| CN-111388489-A | Application of apramycin in preparation of bacterial infectious disease treatment | 苏黎世大学 | 2020-07-10 | — | — | CN | disclosed |
| US-9271993-B2 | Treatment of bacterial infectious diseases | UNIVERSITY OF ZURICH (CH) | 2016-03-01 | — | — | US | disclosed |
| EP-2616079-B1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | UNIV ZÜRICH (CH) | 2015-10-14 | — | — | EP | disclosed |
| CN-103228282-A | Treatment of bacterial infectious diseases | UNIV ZUERICH | 2013-07-31 | — | — | CN | disclosed |
| EP-2616079-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | University of Zürich (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165397-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | ETH ZURICH (CH) | 2013-06-27 | — | — | US | disclosed |
| WO-2012034955-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | UNIVERSITY OF ZURICH (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165397-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | APRT, BPGM, TLR5 | AKR1B1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.